肝细胞外泌体在肝纤维化发生发展过程中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2026.05.001

Abstract

Ma Qingliang, Liu Minghao. Hepatocyte-derived exosomes in pathogenesis of liver fibrosis[J]. Journal of Practical Hepatology, 2026, 29(5): 641-644.

[1] Zhang M, Jing Y, Xu W, et al. The C-type lectin COLEC10 is predominantly produced by hepatic stellate cells and involved in the pathogenesis of liver fibrosis. Cell Death Dis, 2023,14(11):785.
[2] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis. Lancet, 2021,398(10308):1359-1376.
[3] Kim H Y, Yu J H, Chon Y E, et al. Prevalence of clinically significant liver fibrosis in the general population: a systematic review and meta-analysis. Clin Mol Hepatol, 2024,30(Suppl):S199-S213.
[4] Liu Y, Zheng Y, Yang Y, et al. Exosomes in liver fibrosis: the role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications. Front Immunol, 2023,14:1133297.
[5] Shen J, Cao J, Chen M, et al. Recent advances in the role of exosomes in liver fibrosis. J Gastroenterol Hepatol, 2023,38(7):1083-1088.
[6] Wu B, Feng J, Guo J, et al. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. Stem Cell Res Ther, 2022,13(1):494.
[7] Shelke G V, Williamson C D, Jarnik M, et al. Inhibition of endolysosome fusion increases exosome secretion. J Cell Biol, 2023,222(6):e202209084.
[8] Savina A, Fader C M, Damiani M T, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic, 2005,6(2):131-143.
[9] Sundar V, Saraswathi V. Effect of ethanol on exosome biogenesis: possible mechanisms and therapeutic implications. Biomolecules, 2023,13(2):222.
[10] Gurunathan S, Kang M, Jeyaraj M, et al. Platinum nanoparticles enhance exosome release in human lung epithelial adenocarcinoma cancer cells (A549): oxidative stress and the ceramide pathway are key players. Int J Nanomedicine, 2021,16:515-538.
[11] Chen Y, Zhao Y, Yin Y, et al. Mechanism of cargo sorting into small extracellular vesicles. Bioengineered, 2021,12(1):8186-8201.
[12] Thietart S, Rautou P. Extracellular vesicles as biomarkers in liver diseases: a clinician's point of view. J Hepatol, 2020,73(6):1507-1525.
[13] Mirzaei R, Karampoor S, Korotkova N L. The emerging role of miRNA-122 in infectious diseases: mechanisms and potential biomarkers. Pathol Res Pract, 2023,249:154725.
[14] Suga K, Matsui D, Watanabe N, et al. Insight into the exosomal membrane: from viewpoints of membrane fluidity and polarity. Langmuir, 2021,37(38):11195-11202.
[15] Rincón-Riveros A, Lopez L, Villegas E V, et al. Regulation of antitumor immune responses by exosomes derived from tumor and immune cells. Cancers (Basel), 2021,13(4):847.
[16] Hong Y, Ye M, Wang F, et al. MiR-21-3p promotes hepatocellular carcinoma progression via SMAD7/YAP1 regulation. Front Oncol, 2021,11:642030.
[17] Rodrigues P M, Afonso M B, Simão A L, et al. MiR-21-5p promotes NASH-related hepatocarcinogenesis. Liver Int, 2023,43(10):2256-2274.
[18] Chen K, Lin T, Yao W, et al. Adipocytes-derived exosomal miR-122 promotes non-alcoholic fat liver disease progression via targeting Sirt1. Gastroenterol Hepatol, 2023,46(7):531-541.
[19] Ma L, Song H, Zhang C, et al. MiR-192-5p Ameliorates hepatic lipid metabolism in non-alcoholic fatty liver disease by targeting Yy1. Biomolecules, 2023,14(1):34.
[20] Lang Z, Li Y, Lin L, et al. Hepatocyte-derived exosomal miR-146a-5p inhibits hepatic stellate cell EMT process: a crosstalk between hepatocytes and hepatic stellate cells. Cell Death Discov, 2023,9(1):304.
[21] Dong Z, Yang X, Qiu T, et al. Exosomal miR-181a-2-3p derived from citreoviridin-treated hepatocytes activates hepatic stellate cells trough inducing mitochondrial calcium overload. Chem Biol Interact, 2022,358:109899.
[22] Luo X, Luo S, Xu Z, et al. Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease. World J Gastroenterol, 2021,27(14):1419-1434.
[23] Liu B, Wang J, Wang G, et al. Hepatocyte-derived exosomes deliver H2AFJ to hepatic stellate cells and promote liver fibrosis via the MAPK/STMN1 axis activation. Int Immunopharmacol, 2023,115:109605.
[24] Ye Q, Zhou Y, Zhao C, et al. Salidroside inhibits CCl(4)-induced liver fibrosis in mice by reducing activation and migration of HSC induced by liver sinusoidal endothelial cell-derived exosomal SphK1. Front Pharmacol, 2021,12:677810.
[25] Xu W, Mo W, Han D, et al. Hepatocyte-derived exosomes deliver the lncRNA CYTOR to hepatic stellate cells and promote liver fibrosis. J Cell Mol Med, 2024,28(8):e18234.
[26] Seo W, Eun H S, Kim S Y, et al. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by γδ T cells in liver fibrosis. Hepatology, 2016,64(2):616-631.
[27] Van Meteren N, Lagadic-Gossmann D, Podechard N, et al. Extracellular vesicles released by polycyclic aromatic hydrocarbons-treated hepatocytes trigger oxidative stress in recipient hepatocytes by delivering iron. Free Radic Biol Med, 2020,160:246-262.
[28] Hirsova P, Gores G J. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol, 2015,1(1):17-27.
[29] Chen Y, Yang F, Wang Y, et al. Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission. Stem Cell Res Ther, 2025,16(1):116.
[30] Zhang L, Wang C, Hu W, et al. Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE(-/-) mice with minimal side effects. Theranostics, 2023,13(14):5114-5129.
[31] Fukushima M, Dasgupta D, Mauer A S, et al. StAR-related lipid transfer domain 11 (STARD11)-mediated ceramide transport mediates extracellular vesicle biogenesis. J Biol Chem, 2018,293(39):15277-15289.
[32] Du Y, Li Z. Cystatin C alleviates unconjugated bilirubin-induced neurotoxicity by promoting bilirubin clearance from neurocytes via exosomes, dependent on hepatocyte UGT1A1 activity. Transl Neurosci, 2024,15(1):20220357.
[33] Liao T, Chen Y, Hsieh S, et al. Hepatitis C virus-induced exosomal microRNAs and toll-like receptor 7 polymorphism regulate B-cell activating factor. mBio, 2021,12(6):e276421.
[34] Qu M, Zhu H, Zhang X. Extracellular vesicle-mediated regulation of macrophage polarization in bacterial infections. Front Microbiol, 2022,13:1039040.
[35] Costa-Silva B, Aiello N M, Ocean A J, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol, 2015,17(6):816-826.
[36] Luo X, Xu Z, Wu J, et al. Hepatocyte-derived exosomal miR-27a activateshepatic stellate cells through the inhibitionof PINK1-mediated mitophagy in MAFLD. Mol Ther Nucleic Acids, 2021,26:1241-1254.
[37] Li S, Cheng F, Zhang Z, et al. The role of hepatocyte-derived extracellular vesicles in liver and extrahepatic diseases. Biomed Pharmacother, 2024,180:117502.
[38] Li Y, Wu J, Liu R, et al. Extracellular vesicles: catching the light of intercellular communication in fibrotic liver diseases. Theranostics, 2022,12(16):6955-6971.
[39] Munsterman I D, Kendall T J, Khelil N, et al. Extracellular matrix components indicate remodelling activity in different fibrosis stages of human non-alcoholic fatty liver disease. Histopathology, 2018,73(4):612-621.
[40] Wang X, Seo W, Park S H, et al. MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types. Int J Biol Sci, 2021,17(4):1153-1167.
[41] Parlatan U, Ozen M O, Kecoglu I, et al. Label-free identification of exosomes using raman spectroscopy and machine learning. Small, 2023,19(9):e2205519.
[42] 孙东磊,郭金波,王丹丹,等.间充质干细胞外泌体对体外肝星状细胞增殖和活化的影响.实用肝脏病杂志,2023,26(1):11-14.
[43] 张文彦,刘芳,刘梦露,等.非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析.实用肝脏病杂志,2022,25(4):521-525.
[44] Bhadra M, Sachan M. An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection. Heliyon, 2024,10(9):e30328.

Hepatocyte-derived exosomes in pathogenesis of liver fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Han Min, He Mingling, Zhang Dongbang, et al. Prediction of significant liver fibrosis by FibroTouch detection in combination with APRI score in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2026, 29(5): 681-684.
[2]	Guo Hongyan, Wang Rui, Sun Qian. Impact of poorly-controlled blood glucose on oxidative stress and liver fibrosis in patients with type 2 diabetes mellitus and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2026, 29(4): 521-524.
[3]	Yang Hong, Lai Huijun, Ma Lei, et al. Evaluation of liver fibrosis by ultrasound elastography and serum liver fibrosis indexes in patients with schistosomiasis liver disease [J]. Journal of Practical Hepatology, 2026, 29(4): 561-564.
[4]	He Hongmei, Sha Zhihu, Shao Jianguo, et al. Clinical observation of entecavir in combination with Ruangan Sanjie prescription in the treatment of patient with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(2): 179-182.
[5]	Chang Jingxia, Zhang Li, Gai Lin, et al. Diagnostic efficacy of transient elastography with combination of FIB-4 and APRI in assessing significant liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(2): 183-186.
[6]	Huang Yanfang, Li Yuan, Li Zheng, et al. Diagnostic performance of serum tenascin-C level and various liver fibrosis indexes for liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(2): 187-190.
[7]	Zhang Meng, Xu Huaili, Yang Xiaofei, et al. Implication of serum chemokine CXCL12 and its receptors CXCR4 and CXCR7 levels in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2026, 29(2): 205-208.
[8]	Wu Juan, Duan Yan, Qi Yanhua. Comparison of diagnostic efficacy of transient elastography to two-dimensional shear wave elastography in assessing significant liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease [J]. Journal of Practical Hepatology, 2026, 29(2): 217-220.
[9]	Wang Jinping, Zhao Xia, Li Weiming, et al. Assessment of liver fibrosis by Yang’s modules in combination with serum liver fibrosis markers in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(1): 17-20.
[10]	Shi Lingyun, Wu Binbin, Shi Yanli. Implication of serum RBP-4, FGF21 and NF-κB levels in patients with NAFLD and concomitant T2DM [J]. Journal of Practical Hepatology, 2026, 29(1): 53-56.
[11]	Zang Wenjun, Wang Li, Zhang Xia. Clinical observation of Wuling capsule in the treatment of patients with metabolic associated steatohepatitis [J]. Journal of Practical Hepatology, 2026, 29(1): 65-68.
[12]	Li Sisi, Jiang Yanzhen, Fu Zhaoyuan. Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2025, 28(6): 805-808.
[13]	Yang Siqi, Chen Jiawei, Li Shaohan, et al. Improvement of liver steatosis of Coprococcus eutactus in mice with MCD-induced metabolic-associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(6): 813-817.
[14]	Chen Shanshan, Si Xiaochuang, Zhu Jiabao, et al. Diagnostic performance of liver shear wave velocity and various noninvasive parameter combination in the assessment of liver cirrhosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2025, 28(6): 886-889.
[15]	Tang Jie, Jiang Zhengwei, Zhou Bingqing, et al. Diagnostic performance of shear wave elastography combined with APRI and FIB-4 in predicting liver fibrosis in patients with serum HBeAg positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 663-666.